BDTX
- Black Diamond Therapeutics, Inc.
()
Overview
Company Summary
Black Diamond Therapeutics, Inc. (BDTX) is a biotechnology company that focuses on developing small-molecule therapies for cancer treatment. They are specifically focused on understanding and targeting genetic alterations in cancers that drive resistance to current therapies.
BDTX approaches cancer treatment from a precision medicine perspective, recognizing that each patient's tumor has unique genetic mutations and alterations that contribute to its growth. By identifying these specific alterations, the company aims to develop personalized therapies that will selectively target and inhibit the cancer cells, while leaving healthy cells unaffected.
To achieve this, Black Diamond Therapeutics has developed a proprietary platform known as Switch-Engineered Therapeutics (SET), which combines pioneering approaches in structural biology, functional genomics, and machine learning. This platform enables the identification and design of small molecules that selectively target the altered proteins driving cancer growth and drug resistance.
By using their innovative technology, Black Diamond Therapeutics seeks to develop effective and durable therapies for patients who have limited treatment options. Their ultimate goal is to improve patient outcomes by providing targeted therapies that can overcome resistance and address the specific molecular drivers of cancer growth.
Overall, Black Diamond Therapeutics is a biotechnology company striving to revolutionize cancer treatment through innovative precision medicine approaches, with a focus on developing personalized therapies targeting genetic alterations in cancer patients.